Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
NCT04917302Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Oct 2020
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial in schizophrenia, sponsored by China Medical University Hospital. Started Oct 2020; status: recruiting.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04917302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917302.